Baker Danial E
Washington State University, Spokane, USA.
Hosp Pharm. 2017 Jul;52(7):464-468. doi: 10.1177/0018578717724805. Epub 2017 Aug 9.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The September 2017 monograph topics are brigatinib, durvalumab, edaravone, midostaurin, and sarilumab. The MUE is on sarilumab.
每月，《处方集专论服务》的订阅者会收到5至6篇关于新发布或处于3期临床试验后期的药物的资料详实的专论。这些专论面向药学与治疗学委员会。订阅者还会每月收到关于对议程以及药学/护理在职培训有用的药物的1页摘要专论。每月还会提供一份全面的目标药物利用评估/用药评估（DUE/MUE）。订阅后，专论可供订阅者在线获取。专论可定制以满足机构的需求。通过《处方集》的合作，本专栏会发布精选评论。有关《处方集专论服务》的更多信息，请致电866 - 397 - 3433联系威科集团客服。2017年9月的专论主题为布加替尼、度伐鲁单抗、依达拉奉、米哚妥林和萨立鲁单抗。MUE是关于萨立鲁单抗的。
